Drug Trial Radar · NCT01945710
An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
Dec 11, 2012
Primary completion
Oct 2015
Study completion May 17, 2016
Sponsor
- Lead sponsor
- Eisai LimitedEisai
- Sponsor type
- Industry
- First posted
- Sep 18, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study E7389-E044-112 is a Phase 1 study designed to assess the safety, tolerability and preliminary efficacy of eribulin-liposomal formulation (E7389-LF) in patients with solid tumors. This dose-escalation study will determine the maximum tolerated dose, dosing schedules tested, the dose schedule regimen with a more favorable tolerability profile, and a preliminary indication of efficacy.
Conditions
- Solid Tumors
Interventions
Eribulin-LFDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) of Eribulin-LFTime frame: Schedule 1: Cycle 1 (21 days); Schedule 2: Cycle 1 (28 days)
- Dose Limiting Toxicities at the Indicated Dose Levels, as an Assessment of Dosing FrequencyTime frame: Cycle 1 of Dose Escalation part in Schedule 1 and Schedule 2
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
UCL Cancer Institute
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Royal Marsden Hospital
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.